{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:29:32Z","timestamp":1790990972403,"version":"4.1.0"},"reference-count":72,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T00:00:00Z","timestamp":1625356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1C1C1008843"],"award-info":[{"award-number":["2021R1C1C1008843"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Global Research Development Center Program","award":["2018K1A4A3A01064257"],"award-info":[{"award-number":["2018K1A4A3A01064257"]}]},{"name":"Priority Research Center Program, Ministry of Education","award":["2019R1A6A1A11034536"],"award-info":[{"award-number":["2019R1A6A1A11034536"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>It is yet unknown whether the intravenous administration route alone can fully account for the exacerbation of medication-related osteonecrosis of the jaw (MRONJ). The purpose of this retrospective study was to identify the potential role of the bisphosphonate (BP) administration route as an independent prognostic factor for non-cancerous, stage III MRONJ patients. Bone samples were retrospectively obtained from two groups of osteoporosis patients who underwent surgery for the treatment of stage III MRONJ. Among the subjects, 10 had a history of only oral BP consumption and 10 of intravenous (IV) BP administration. The samples were assessed for osteoclast morphology and immunohistochemical expression of the receptor activator of NF-\u03baB ligand (RANKL), osteoprotegerin (OPG), and potassium calcium-activated channel subfamily N member 4 (Kcnn4). Although the osteoclasts derived from both groups exhibited no significant differences in the mean quantity, diameter, and nuclearity, significantly attenuated tartrate-resistant acid phosphatase activity was noted among the IV BP-induced MRONJ bones compared to those of the oral BP group. Significant suppression of the RANKL\/OPG ratio and Kcnn4 expression among the retrieved bones of IV BP group patients was also noted. Our results indicate the potential of the BP administration route as an independent prognostic factor for advanced-stage MRONJ, regardless of the dosage or indication for which the BP was prescribed.<\/jats:p>","DOI":"10.3390\/jcm10132988","type":"journal-article","created":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T22:34:36Z","timestamp":1625438076000},"page":"2988","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of the Effect of Oral Versus Intravenous Bisphosphonate Administration on Osteoclastogenesis in Advanced-Stage Medication-Related Osteonecrosis of the Jaw Patients"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5959-4080","authenticated-orcid":false,"given":"Hye-Won","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, College of Dentistry, Dankook University, 119 Dandae-ro, Cheonan 31116, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Woo","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, College of Dentistry, Dankook University, 119 Dandae-ro, Cheonan 31116, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8678-5459","authenticated-orcid":false,"given":"Jung-Hwan","family":"Lee","sequence":"additional","affiliation":[{"name":"Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan 31116, Korea"},{"name":"UCL Eastman-Korea Dental Medicine Innovation Centre, Dankook University, Cheonan 31116, Korea"},{"name":"Department of Nanobiomedical Science & BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dankook University, Chungnam, Cheonan 31116, Korea"},{"name":"Department of Biomaterials Science, College of Dentistry, Dankook University, Chungnam, Cheonan 31116, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9596-7481","authenticated-orcid":false,"given":"Moon-Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, College of Dentistry, Dankook University, 119 Dandae-ro, Cheonan 31116, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.oooo.2019.02.014","article-title":"Association between biomarkers and medication-related osteonecrosis of the jaws: A systematic review","volume":"127","author":"Moraschini","year":"2019","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12967-017-1230-8","article-title":"Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: A comparison with osteoradionecrosis and osteomyelitis","volume":"15","author":"Gross","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"36129","DOI":"10.1038\/srep36129","article-title":"Skeletal Site-Specific Effects of Zoledronate on In Vivo Bone Remodeling and In Vitro BMSCs Osteogenic Activity","volume":"7","author":"Gong","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jbmr.37","article-title":"Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice","volume":"25","author":"Kikuiri","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.joms.2020.05.037","article-title":"Can Surgical Management Improve Resolution of Medication-Related Osteonecrosis of the Jaw at Early Stages? A Prospective Cohort Study","volume":"78","author":"Giudice","year":"2020","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.4103\/ijdr.IJDR_689_19","article-title":"Usefulness of advanced-platelet rich fibrin (A-PRF) and injectable-platelet rich fibrin (i-PRF) in the management of a massive medication-related osteonecrosis of the jaw (MRONJ): A 5-years follow-up case report","volume":"31","author":"Giudice","year":"2020","journal-title":"Indian J. Dent. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jcms.2017.05.028","article-title":"What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review","volume":"45","author":"Aljohani","year":"2017","journal-title":"J. Craniomaxillofac. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1016\/j.ajpath.2014.07.010","article-title":"Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-kappaB ligand antibody in mice","volume":"184","author":"Williams","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/0022034514564187","article-title":"Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition","volume":"94","author":"Nagaoka","year":"2015","journal-title":"J. Dent. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ijom.2015.03.013","article-title":"Comparison of the prognosis of bisphosphonate-related osteonecrosis of the jaw caused by oral and intravenous bisphosphonates","volume":"44","author":"Shintani","year":"2015","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: Mechanisms of action","volume":"97","author":"Rodan","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00232-014-9747-8","article-title":"Effects of ibandronate sodium, a nitrogen-containing bisphosphonate, on intermediate-conductance calcium-activated potassium channels in osteoclast precursor cells (RAW 264.7)","volume":"248","author":"Wu","year":"2015","journal-title":"J. Membr. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S8756-3282(01)00615-9","article-title":"Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis","volume":"29","author":"Rodan","year":"2001","journal-title":"Bone"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4049\/jimmunol.1701170","article-title":"Ca(2+)-Dependent Regulation of NFATc1 via KCa3.1 in Inflammatory Osteoclastogenesis","volume":"200","author":"Grossinger","year":"2018","journal-title":"J. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"ref_19","first-page":"204","article-title":"Osteoclastogenesis-current knowledge and future perspectives","volume":"8","author":"Yavropoulou","year":"2008","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-011-0749-z","article-title":"RANKL\/RANK-beyond bones","volume":"89","author":"Hanada","year":"2011","journal-title":"J. Mol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4068\/cmj.2016.52.1.12","article-title":"Signaling Pathways in Osteoclast Differentiation","volume":"52","author":"Kim","year":"2016","journal-title":"Chonnam Med. J."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Maisani, M., Pezzoli, D., Chassande, O., and Mantovani, D. (2017). Cellularizing hydrogel-based scaffolds to repair bone tissue: How to create a physiologically relevant micro-environment?. J. Tissue Eng., 8.","DOI":"10.1177\/2041731417712073"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yu, H.-S., Kim, J.-J., Kim, H.-W., Lewis, M.P., and Wall, I. (2016). Impact of mechanical stretch on the cell behaviors of bone and surrounding tissues. J. Tissue Eng., 7.","DOI":"10.1177\/2041731415618342"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11914-007-0024-y","article-title":"The RANKL\/RANK\/OPG pathway","volume":"5","author":"Boyce","year":"2007","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.tripleo.2009.10.042","article-title":"RANK\/RANKL\/OPG role in distraction osteogenesis","volume":"109","author":"Rey","year":"2010","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/cid.12297","article-title":"Biomarkers for Bisphosphonate-Related Osteonecrosis of the Jaw","volume":"18","author":"Kim","year":"2016","journal-title":"Clin. Implant. Dent. Relat. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.celrep.2014.07.032","article-title":"Kcnn4 is a regulator of macrophage multinucleation in bone homeostasis and inflammatory disease","volume":"8","author":"Kang","year":"2014","journal-title":"Cell Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"16437","DOI":"10.18632\/aging.103710","article-title":"KCNN4 is a diagnostic and prognostic biomarker that promotes papillary thyroid cancer progression","volume":"12","author":"Wen","year":"2020","journal-title":"Aging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/jim-2019-001073","article-title":"KCNN4 promotes invasion and metastasis through the MAPK\/ERK pathway in hepatocellular carcinoma","volume":"68","author":"Li","year":"2020","journal-title":"J. Investig. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/ddr.20467","article-title":"The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression","volume":"72","author":"Lam","year":"2011","journal-title":"Drug Dev. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bbrc.2017.10.072","article-title":"Integrated expression profiling of potassium channels identifys KCNN4 as a prognostic biomarker of pancreatic cancer","volume":"494","author":"Jiang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zhang, P., Yang, X., Yin, Q., Yi, J., Shen, W., Zhao, L., Zhu, Z., and Liu, J. (2016). Inhibition of SK4 Potassium Channels Suppresses Cell Proliferation, Migration and the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154471"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ijc.32121","article-title":"The potassium channel KCa3.1 promotes cell proliferation by activating SKP2 and metastasis through the EMT pathway in hepatocellular carcinoma","volume":"145","author":"Du","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Rabjerg, M., Olivan-Viguera, A., Hansen, L.K., Jensen, L., Sevelsted-Moller, L., Walter, S., Jensen, B.L., Marcussen, N., and Kohler, R. (2015). High expression of KCa3.1 in patients with clear cell renal carcinoma predicts high metastatic risk and poor survival. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122992"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/ijc.29490","article-title":"Epigenetic dysregulation of KCa 3.1 channels induces poor prognosis in lung cancer","volume":"137","author":"Bulk","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s12013-014-0497-0","article-title":"Effects of Intermediate-Conductance Ca(2+)-Activated K(+) Channels on Human Endometrial Carcinoma Cells","volume":"72","author":"Zhang","year":"2015","journal-title":"Cell Biochem. Biophys."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1038\/onc.2009.25","article-title":"Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry","volume":"28","author":"Roudbaraki","year":"2009","journal-title":"Oncogene"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1742-7843.2005.pto_176.x","article-title":"In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts","volume":"97","author":"Kellinsalmi","year":"2005","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Giudice, A., Antonelli, A., Chiarella, E., Baudi, F., Barni, T., and Di Vito, A. (2020). The Case of Medication-Related Osteonecrosis of the Jaw Addressed from a Pathogenic Point of View. Innovative Therapeutic Strategies: Focus on the Most Recent Discoveries on Oral Mesenchymal Stem Cell-Derived Exosomes. Pharmaceuticals, 13.","DOI":"10.3390\/ph13120423"},{"key":"ref_42","first-page":"963689720948497","article-title":"Dose-Dependent Effects of Zoledronic Acid on Human Periodontal Ligament Stem Cells: An In Vitro Pilot Study","volume":"29","author":"Chiarella","year":"2020","journal-title":"Cell Transplant."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Cheng, T.L., Murphy, C.M., Ravarian, R., Dehghani, F., Little, D.G., and Schindeler, A. (2015). Bisphosphonate-adsorbed ceramic nanoparticles increase bone formation in an injectable carrier for bone tissue engineering. J. Tissue Eng., 6.","DOI":"10.1177\/2041731415609448"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bone.2018.05.001","article-title":"Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice","volume":"112","author":"Kuroshima","year":"2018","journal-title":"Bone"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5125\/jkaoms.2016.42.4.193","article-title":"Evaluation of the predisposing factors and involved outcome of surgical treatment in bisphosphonate-related osteonecrosis of the jaw cases including bone biopsies","volume":"42","author":"Kim","year":"2016","journal-title":"J. Korean Assoc. Oral Maxillofac. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00784-018-2579-7","article-title":"Immediate implant placement following 1-year treatment with oral versus intravenous bisphosphonates: A histomorphometric canine study on peri-implant bone","volume":"23","author":"Khojasteh","year":"2019","journal-title":"Clin. Oral Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.joms.2008.12.007","article-title":"Reconstruction of defects caused by bisphosphonate-induced osteonecrosis of the jaws","volume":"67","author":"Marx","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.joms.2009.01.006","article-title":"The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Carlson","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1007\/s00784-018-2349-6","article-title":"Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro","volume":"22","author":"Jung","year":"2018","journal-title":"Clin. Oral Investig."},{"key":"ref_52","first-page":"315","article-title":"Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis","volume":"60","author":"Heijckmann","year":"2002","journal-title":"Neth. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0169-409X(00)00061-2","article-title":"Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption","volume":"42","author":"Ezra","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","article-title":"Efficacy and safety of ibandronate given by intravenous injection once every 3 months","volume":"34","author":"Adami","year":"2004","journal-title":"Bone"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","article-title":"Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: Results from a long-term comparative study","volume":"14","author":"Ringe","year":"2003","journal-title":"Osteoporos Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","article-title":"Three Monthly Intravenous Injections of Ibandronate in the Treatment of Postmenopausal Osteoporosis","volume":"103","author":"Burckhardt","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1007\/s00198-005-1862-z","article-title":"The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis","volume":"16","author":"Vis","year":"2005","journal-title":"Osteoporos Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00198-011-1800-1","article-title":"Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis","volume":"23","author":"Roux","year":"2012","journal-title":"Osteoporos Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamainternmed.2015.0747","article-title":"Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: A randomized clinical trial","volume":"175","author":"Greenspan","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density","volume":"346","author":"Reid","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2217\/fon.13.28","article-title":"Zoledronic acid to prevent and treat cancer metastasis: New prospects for an old drug","volume":"9","author":"Young","year":"2013","journal-title":"Future Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1517\/14740338.6.6.663","article-title":"Renal safety of intravenous bisphosphonates in the treatment of osteoporosis","volume":"6","author":"Lewiecki","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy","volume":"360","author":"Weinstein","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1472-6890-14-31","article-title":"Giant osteoclasts in patients under bisphosphonates","volume":"14","author":"Trombetti","year":"2014","journal-title":"BMC Clin. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.joms.2013.05.023","article-title":"Immunohistochemical detection of receptor activator nuclear kappaB ligand and osteoprotegerin in odontogenic cysts and tumors","volume":"71","author":"Galvao","year":"2013","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ijom.2013.02.008","article-title":"The effects of chronic zoledronate usage on the jaw and long bones evaluated using RANKL and osteoprotegerin levels in an animal model","volume":"42","author":"Cankaya","year":"2013","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00784-010-0477-8","article-title":"Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro","volume":"16","author":"Koch","year":"2012","journal-title":"Clin. Oral Investig."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.bone.2006.08.003","article-title":"Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget\u2019s disease of bone","volume":"40","author":"Martini","year":"2007","journal-title":"Bone"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/13\/2988\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:25:52Z","timestamp":1760163952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/13\/2988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,4]]},"references-count":72,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["jcm10132988"],"URL":"https:\/\/doi.org\/10.3390\/jcm10132988","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,4]]}}}